Conferences

Improving Outcomes in Corneal Endothelial Disease With Cell Therapy

January 20th 2022

Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.

Optogenetics Device With Gene Therapy is Safe, Efficacious in Retinitis Pigmentosa

December 13th 2021

Following GS030 optogenetic therapy, the first treated patient was able to locate and count objects on a table and could identify crosswalks in the street.

Gene Therapy for Diabetic Macular Edema Shows Mixed Efficacy, Safety

December 6th 2021

Findings from the phase 2 INFINITY trial identified dose-dependent safety outcomes of ADVM-022 in patients with diabetic macular edema.

Gene Therapy Optogenetics Combination Efficacious in Retinitis Pigmentosa: José-Alain Sahel, MD

November 21st 2021

The professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.

RGX-314 Gene Therapy Efficacious in Wet AMD: Robert L. Avery, MD

November 19th 2021

The chief executive officer of California Retina Consultants discussed the positive results of RGX-314 gene therapy in wet AMD.

OpRegen Shows Durable Efficacy in Dry AMD Geographic Atrophy

November 16th 2021

The Doheny Image Reading and Research Lab is leading a sub study to analyze OCT images with their proprietary 3D-OCTOR software.

Gene Therapy Represents New Era for Inherited Retinal Disease Treatment

April 6th 2021

Physician offers patient counseling pearls for selected retinal diseases.

New Data Shows Promise for Investigative XLRP Gene Therapy

November 13th 2020

The study presented at AAO provides an update on previously shared 6-month data from earlier this year.